# PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

> **NCT04129931** · PHASE2 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 950 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** MCT
- **DRUG:** Clazakizumab
- **DRUG:** Broncho-Vaxom
- **DRUG:** Imatinib Mesylate
- **DRUG:** Cavosonstat
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04129931
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2025-02-19
- **Final completion:** 2025-03-19
- **Target enrollment:** 950 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129931, "PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT04129931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*